Form 483

ImprimisRx NJ Form 483, 2022-08-05

FDA issued a Form 483 to ImprimisRx NJ on 2022-08-05 with 7 public-safe observations.

483· Form 483 issuedHuman Drugs7 observations

ImprimisRx NJ · Ledgewood, United States · Issued August 5, 2022

Overview

  • 7 public-safe observations are available for this inspection.
  • 1 structured CFR citation is represented.
  • 3 investigators are tied to this Form 483.

Inspectional observations

Each observation cites the regulation FDA found the firm out of compliance with.

5 Aug 2022
FDCA 501(a)(2)(A)

Air flow quality, higher classified area

Cited by Sena G Dissmeyer, Tekalign Wondimu, Amy N Chen

5 Aug 2022
FDCA 501(a)(2)(A)

Cleanliness, ISO-classified areas

Cited by Sena G Dissmeyer, Tekalign Wondimu, Amy N Chen

5 Aug 2022
FDCA 501(a)(2)(A)

Disinfecting materials, aseptic processing area

Cited by Sena G Dissmeyer, Tekalign Wondimu, Amy N Chen

5 Aug 2022
FDCA 501(a)(2)(A)

Dust-collecting overhangs, surrounding area of ISO 5

Cited by Sena G Dissmeyer, Tekalign Wondimu, Amy N Chen

5 Aug 2022
FDCA 501(a)(2)(A)

Inadequate sporicidal agents, cleanroom and ISO 5 area

Cited by Sena G Dissmeyer, Tekalign Wondimu, Amy N Chen

Inspected site

INImprimisRx NJLedgewood, United States

Inspection team

Cited regulations

CFR citations associated with this Form 483.

CitationWhat it coversCited
FDCA 501(a)(2)(A)Cited across public-safe Form 483 observations7x

Source document

PDF
PDF available

Form 483 source document

The source document is available to authorized Atlas users.

Full 483 report

Get the verbatim text of all 7 observations

The source PDF, so your team sees exactly what was cited and how it was answered.

  • The site's full inspection history around this Form 483
  • Whether these citations escalated to a warning letter
  • The investigators involved and the citations they repeat elsewhere